
<html>

<head>





</head>

<body lang="EN-US" link="blue" vlink="purple" style="text-justify-trim:punctuation;">

<div>

<p align="right" style="font-weight:bold;letter-spacing:0pt;margin:0in 0in .0001pt;text-align:right;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;">Exhibit 99.1</font></b></p>

<p style="font-weight:bold;letter-spacing:0pt;margin:0in 0in .0001pt;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:normal;">&nbsp;</font></b></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font style="font-weight:bold;letter-spacing:0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;">CardioTech International Inc. Closes $2.735
Million Private Placement with Institutional Investors</font></b></font><br><br></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">WILMINGTON, MA, December&nbsp;22, 2004;
CardioTech International, Inc. (AMEX:&#160;
CTE), announced today the closing of a $2,735,006 million private placement
of its common stock with 7 institutional investors. The offering was priced at
$2.40 per share resulting in an initial issuance of 1,139,586 shares of
CardioTech&#146;s common stock. The investors also received five-year warrants to
purchase an additional 569,793 shares of common stock at an exercise price of
$3.00 per share and additional investment rights to purchase 1,139,586 shares
of CardioTech&#146;s common stock at $2.40 per share during the period commencing on
the closing date and ending 90 days after the effective date of a registration
statement that we intend to file. CardioTech has undertaken to file such
registration statement covering the common stock issued in the placement, the
common stock underlying the warrants and the common stock underlying the
additional investment rights.</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Michael Szycher, PhD., CEO of CardioTech, commented, &#147;This financing is
an important step in the growth of CardioTech.&#160;
We believe that the financing represents a vote of confidence by the
institutional investors in our Company, in our business plan and our management&#146;s
ability to execute on the plan.</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">About CardioTech </font></u></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CardioTech International, Inc. maintains operations in Wilmington,
Massachusetts, Plymouth, Minnesota and Rancho Santa Margarita, California.
CardioTech focuses on developing, manufacturing and marketing devices to
surgically treat cardiovascular disease. Current revenue sources for CardioTech
include patented polyurethanes, contract manufacturing, and disposables used
during cardiopulmonary bypass procedures. CardioTech is currently in human
clinical trials with a synthetic coronary artery bypass graft that addresses a
$1.5 billion annual market. Additionally, CardioTech has partnered with Implant
Sciences and CorNova to develop a drug-eluting stent that addresses a $1
billion international market.</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CardioTech believes that this release contains forward-looking
statements that are subject to risks and uncertainties. Such statements are
based on management&#146;s current expectations and are subject to facts that could
cause results to differ materially from the forward-looking statements. For
further information you are encouraged to review CardioTech&#146;s filings with the
Securities and Exchange Commission.</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman">&nbsp;</font></p>

<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
 <tr>
  <td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.12%;"><p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p></td>
  <td width="93%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:93.88%;"><p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Investor contact:</font></p></td>
 </tr>
 <tr>
  <td width="6%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:6.78%;"><p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p></td>
  <td width="93%" valign="top" style="padding:0in 0in 0in 0in;width:93.22%;"><p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Aurelius Consulting Group:</font></p></td>
 </tr>
 <tr>
  <td width="6%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:6.78%;"><p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p></td>
  <td width="93%" valign="top" style="padding:0in 0in 0in 0in;width:93.22%;"><p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Dave Gentry or Ed Sasso, 407/644-4256</font></p></td>
 </tr>
 <tr>
  <td width="6%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:6.78%;"><p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p></td>
  <td width="93%" valign="top" style="padding:0in 0in 0in 0in;width:93.22%;"><p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">dave@aurcg.com</font></p></td>
 </tr>
 <tr>
  <td width="6%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:6.78%;"><p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p></td>
  <td width="93%" valign="top" style="padding:0in 0in 0in 0in;width:93.22%;"><p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">http://www.runonideas.com</font></p></td>
 </tr>
 <tr height="0">
  <td width="46" style="border:none;"></td>
  <td width="5" style="border:none;"></td>
  <td width="697" style="border:none;"></td>
 </tr>
</table>

<p style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p><p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:11.0pt;">

<hr size="2" width="100%" noshade color="gray" align="left">

</font></p><p style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:11.0pt;">&nbsp;</font></p></div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\hkrishn\04-15265-1\task261753\15265-1-mm.htm',USER='hkrishnamurthy',CD='Dec 23 15:52 2004' -->


</body>

</html>

